These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 11729364

  • 1. Comparison of GP IIB/IIIA inhibitors and their activity as measured by aggregometry, flow cytometry, single platelet counting, and the rapid platelet function analyzer.
    Matzdorff AC, Kühnel G, Kemkes-Matthes B, Voss R.
    J Thromb Thrombolysis; 2001 Oct; 12(2):129-39. PubMed ID: 11729364
    [Abstract] [Full Text] [Related]

  • 2. In vitro dose response to different GPIIb/IIIa-antagonists: inter-laboratory comparison of various platelet function tests.
    Harder S, Klinkhardt U, Graff J, Westrup D, Kirchmaier CM, Glusa E, Mascelli MA, Marciniak SJ, Just A, Lösche W, Breddin HK.
    Thromb Res; 2001 Apr 01; 102(1):39-48. PubMed ID: 11323013
    [Abstract] [Full Text] [Related]

  • 3. Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests: relevance for monitoring long-term glycoprotein IIb/IIIa inhibition.
    Osende JI, Fuster V, Lev EI, Shimbo D, Rauch U, Marmur JD, Richard M, Varon D, Badimon JJ.
    Circulation; 2001 Mar 20; 103(11):1488-91. PubMed ID: 11257073
    [Abstract] [Full Text] [Related]

  • 4. Rapid platelet-function assay: an automated and quantitative cartridge-based method.
    Smith JW, Steinhubl SR, Lincoff AM, Coleman JC, Lee TT, Hillman RS, Coller BS.
    Circulation; 1999 Feb 09; 99(5):620-5. PubMed ID: 9950658
    [Abstract] [Full Text] [Related]

  • 5. The use of the point of care Helena ICHOR/Plateletworks and the Accumetrics Ultegra RPFA for assessment of platelet function with GPIIB-IIIa antagonists.
    White MM, Krishnan R, Kueter TJ, Jacoski MV, Jennings LK.
    J Thromb Thrombolysis; 2004 Dec 09; 18(3):163-9. PubMed ID: 15815877
    [Abstract] [Full Text] [Related]

  • 6. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
    Proimos G.
    J Thromb Thrombolysis; 2001 Apr 09; 11(2):99-110. PubMed ID: 11406724
    [Abstract] [Full Text] [Related]

  • 7. Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials.
    Bertram U, Moser M, Peter K, Kuecherer HF, Bekeredjian R, Straub A, Nordt TK, Bode C, Ruef J.
    J Thromb Thrombolysis; 2002 Dec 09; 14(3):197-203. PubMed ID: 12913399
    [Abstract] [Full Text] [Related]

  • 8. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.
    Mascelli MA, Worley S, Veriabo NJ, Lance ET, Mack S, Schaible T, Weisman HF, Jordan RE.
    Circulation; 1997 Dec 02; 96(11):3860-6. PubMed ID: 9403608
    [Abstract] [Full Text] [Related]

  • 9. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
    Matzdorff A, Voss R.
    Thromb Res; 2006 Dec 02; 117(3):307-14. PubMed ID: 15894353
    [Abstract] [Full Text] [Related]

  • 10. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA.
    Circulation; 2002 Sep 17; 106(12):1470-6. PubMed ID: 12234950
    [Abstract] [Full Text] [Related]

  • 11. A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban.
    Simon DI, Liu CB, Ganz P, Kirshenbaum JM, Piana RN, Rogers C, Selwyn AP, Popma JJ.
    Catheter Cardiovasc Interv; 2001 Apr 17; 52(4):425-32. PubMed ID: 11285593
    [Abstract] [Full Text] [Related]

  • 12. Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting.
    Neumann FJ, Hochholzer W, Pogatsa-Murray G, Schömig A, Gawaz M.
    J Am Coll Cardiol; 2001 Apr 17; 37(5):1323-8. PubMed ID: 11300442
    [Abstract] [Full Text] [Related]

  • 13. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists.
    Storey RF, Wilcox RG, Heptinstall S.
    Circulation; 1998 Oct 20; 98(16):1616-21. PubMed ID: 9778326
    [Abstract] [Full Text] [Related]

  • 14. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
    Marciniak SJ, Jordan RE, Mascelli MA.
    Thromb Haemost; 2001 Mar 20; 85(3):539-43. PubMed ID: 11307828
    [Abstract] [Full Text] [Related]

  • 15. High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists.
    Kereiakes DJ, Broderick TM, Roth EM, Whang D, Mueller M, Lacock P, Anderson LC, Howard W, Blanck C, Schneider J, Abbottsmith CA.
    J Thromb Thrombolysis; 2000 Feb 20; 9(2):149-55. PubMed ID: 10613996
    [Abstract] [Full Text] [Related]

  • 16. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM.
    Am Heart J; 1999 Oct 20; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [Abstract] [Full Text] [Related]

  • 17. Variability of platelet aggregate dispersal with glycoprotein IIb-IIIa antagonists eptifibatide and abciximab.
    Speich HE, Earhart AD, Hill SN, Cholera S, Kueter TJ, Smith JN, White MM, Jennings LK.
    J Thromb Haemost; 2009 Jun 20; 7(6):983-91. PubMed ID: 19548907
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of abciximab induced platelet blockade using a rapid point of care assay.
    Kereiakes DJ, Mueller M, Howard W, Lacock P, Anderson LC, Broderick TM, Roth EM, Whang DD, Abbottsmith CW.
    J Thromb Thrombolysis; 1999 Jun 20; 7(3):265-76. PubMed ID: 10375388
    [Abstract] [Full Text] [Related]

  • 19. The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy.
    Wheeler GL, Braden GA, Steinhubl SR, Kereiakes DJ, Kottke-Marchant K, Michelson AD, Furman MI, Mueller MN, Moliterno DJ, Sane DC.
    Am Heart J; 2002 Apr 20; 143(4):602-11. PubMed ID: 11923796
    [Abstract] [Full Text] [Related]

  • 20. A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologies.
    Storey RF, May JA, Wilcox RG, Heptinstall S.
    Thromb Haemost; 1999 Oct 20; 82(4):1307-11. PubMed ID: 10544919
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.